#USA #San Francisco #FDA #ImmunityBio #Anktiva

ImmunityBio Faces Class Action Lawsuit Amid FDA Warnings

ImmunityBio, Inc. (NASDAQ: IBRX) has found itself at the center of a major class action lawsuit that could have serious repercussions for the biotechnology company and its investors. This legal action comes on the heels of a warning from the U.S. Food and Drug Administration (FDA), which raised concerns about misleading claims made regarding ImmunityBio's flagship product, Anktiva. This controversy has led to a staggering drop in the company’s stock price, wiping out nearly $2 billion in market capitalization and raising questions about its ethical practices.

Background on ImmunityBio and the Allegations

ImmunityBio is primarily engaged in the research and development of innovative immunotherapies aimed at boosting the body's immune response to cancer and infectious diseases. Anktiva is an FDA-approved treatment specifically designed for non-muscle invasive bladder cancer (NMIBC). However, during a podcast aired on January 19, 2026, Dr. Patrick Soon-Shiong, the executive chairman and Chief Scientific and Medical Officer, made statements suggesting that Anktiva could potentially treat all forms of cancer, a claim that was quickly flagged by the FDA as misleading.

The class action lawsuit seeks to represent investors who purchased ImmunityBio securities from January 19, 2026, to March 24, 2026, when the FDA's warning led to a significant decline in the stock price. Legal firm Hagens Berman, known for its focus on investors' rights, is leading the charge against ImmunityBio, alleging that the company violated federal securities laws by providing inaccurate and misleading information regarding Anktiva’s efficacy.

The FDA Warning and Its Implications

The pivotal moment in this unfolding drama came on March 24, 2026, when reports surfaced indicating that the FDA had sent a formal warning letter to ImmunityBio. The letter stated that the promotional materials associated with Anktiva were misleading and created false impressions about the drug's capabilities. Specifically, the FDA pointed out that Anktiva should not be presented as a cure for all cancers when there is no supporting data to substantiate such claims.

Furthermore, the FDA found the assertions made in a TV advertisement and the aforementioned podcast contributed to a misunderstanding regarding the treatment's effectiveness. The agency stated, “the representations in the TV ad and podcast misleadingly suggest that Anktiva will allow all NMIBC patients treated with Anktiva to be cancer-free for the long term, when this has not been demonstrated.” This declaration highlighted serious concerns not only about ImmunityBio's marketing ethics but also about public health if unverified claims lead patients to make uninformed treatment decisions.

Investor Sentiment and Financial Repercussions

As news of the FDA warning broke, ImmunityBio’s stock plummeted by over 21% in a single day, marking a significant loss for investors and leading to the impending class action. Investors who acted on the inaccurate promotional materials felt highly deceived, resulting in the filing of the lawsuit to recover their losses.

Reed Kathrein, a partner at Hagens Berman, expressed concern over ImmunityBio's practices, stating, “We’re investigating claims that ImmunityBio intentionally misled investors about Anktiva efficacy and indications.” Such sentiments echo the frustrations of many shareholders who trusted the company’s marketing and innovation promise in the biotechnology space.

Looking Forward

The class action lawsuit against ImmunityBio may serve as a formidable reminder of the responsibilities that companies in the life sciences realm have towards their investors and patients alike. As the legal proceedings unfold, investors who believe they have been wronged, or those who might have vital information related to the case, are encouraged to step forward. The Hagens Berman firm continues to solicit individuals to submit evidence or insights that may influence the direction of the case.

Given the complexities outlined, enhancements to the regulations surrounding pharmaceutical marketing practices appeared increasingly necessary. As the FDA focuses on ensuring that companies are held accountable for misleading claims, the future implications on ImmunityBio and its stakeholders remain uncertain.

The broader biotechnology sector will be closely monitoring this situation as it develops, as it not only affects ImmunityBio but could also set precedents for how other companies handle the marketing of their products and the disclosures they provide to investors.

For more information and ongoing updates about the class action lawsuit involving ImmunityBio, you can visit the Hagens Berman website or reach out directly to the firm’s legal team.